Skip to main content

Advertisement

Table 3 Efficacy and safety outcomes of clinical trials with NOACs for the treatment of VTE

From: The diagnosis and treatment of venous thromboembolism in Asian patients

All Patients Asian Patients
Trial N VTE recurrencea Major or CRNM bleedinga Trial N VTE recurrencea Major or CRNM bleedinga
Dabigatran     Dabigatran    
RE-COVER [114] 2539 1.10 (0.65–1.84) 0.63 (0.47–0.84) RE-COVER RE-COVER II Asian subanalysisb 557 2.55 (0.66–9.90) 0.63 (0.33–1.19)
RE-COVER II [115] 2568 1.08 (0.64–1.80) 0.62 (0.45–0.84)     
Rivaroxaban     Rivaroxaban    
EINSTEIN-DVT [116] 3449 0.68 (0.44–1.04) 0.97 (0.76–1.22) EINSTEIN-DVT and PE Asian subanalysis [111] 439 1.04 (0.36–3.0) 0.63 (0.31–1.26)
EINSTEIN-PE [117] 4832 1.12 (0.75–1.68) 0.90 (0.76–1.07) J-EINSTEIN DVT and PE [73] 100 3.9% (−3.4 to 23.8)c Rivaroxaban 7.8% UFH/warfarin 5.3%d
Apixaban     Apixaban    
AMPLIFY [119] 5395 0.84 (0.60–1.18) 0.44 (0.36–0.55) AMPLIFY-J [112] 80 Apixaban 0/40 UFH/warfarin 1/40e Apixaban 7.5% UFH/warfarin 28.2%f
Edoxaban     Edoxaban    
Hokusai-VTE [120] 8240 0.89 (0.70–1.13) 0.81 (0.71–0.94) Hokusai-VTE Asian subanalysis [110] 1109 0.64 (0.34–1.19) 0.56 (0.40–0.78)
  1. aValues are hazard ratio (95% confidence interval) unless otherwise indicated
  2. bData on file
  3. cAbsolute risk difference (95% confidence interval)
  4. dPercentage of patients with CRNM bleeding
  5. eNumber of patients
  6. fPercentage of patients
  7. CRNM clinically relevant nonmajor, DVT deep vein thrombosis, NOAC non-vitamin K antagonist oral anticoagulant, PE pulmonary embolism, UFH unfractionated heparin, VTE venous thromboembolism